Skip to content

BioEvocs - Testing the 'poo sniffer' in children and young people with eosinophilic esophagitis

BioEvocs - Faecal volatile organic compounds in children with eosinophilic oesophagitis: potential as non-invasive biomarkers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN10653410
Enrollment
120
Registered
2023-12-20
Start date
2023-10-24
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic esophagitis Digestive System

Interventions

This will be a case-control feasibility study that collects faecal samples from patients undergoing diagnostic assessment or treatment for EoE, and from normal controls and controls of patients with o

Sponsors

Alder Hey Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: For EoE: Children attending endoscopy or clinic for known EoE or to investigate symptoms indicating flare-up of disease symptoms contacting the department, or patients found to have EoE who are awaiting treatment. For controls: Control patients identified in gastroenterology or ophthalmology outpatient clinics

Exclusion criteria

Exclusion criteria: 1. Patients unable to provide a faecal sample 2. Patients and parents unable to give informed consent 3. Previous colonic resection 4. Patients on an elemental diet unrelated to EoE 5. Current or treatment with systemic antibiotics in the previous 4 weeks 6. Patients with known chronic gastro-intestinal infection or chronic diarrhoea 7. Patients with confirmed and clinically significant irritable bowel syndrome

Design outcomes

Primary

MeasureTime frame
Patterns of volatile organic compounds associated with active EoE, measured using gas chromatography-mass spectrometry at baseline and 3 months

Secondary

MeasureTime frame
1. Patterns of volatile organic compounds treated with medical (oral viscous budesonide) or dietetic (elimination diet) treatment, measured using gas chromatography-mass spectrometry at baseline and 3 months 2. Patient disease activity measured using Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) score at baseline and 3 months 3. Nutritional status and atopic background measured using Environmental questionnaire at baseline 4. Microbiome selected analysis and CGR (Centre for Genomic Research) sequencing of fecal sample at baseline and 3 months

Countries

England, United Kingdom

Contacts

Public ContactMarcus;Chris Auth;Probert

;

marcus.auth@alderhey.nhs.uk;Chris.Probert@liverpool.ac.uk+44 (0)1512284811 ;+44 (0)151 795 4010

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026